ECSP993264A - DERIVATIVES OF CYCLIC HYDRAZINE - Google Patents
DERIVATIVES OF CYCLIC HYDRAZINEInfo
- Publication number
- ECSP993264A ECSP993264A ECSP993264A ECSP993264A EC SP993264 A ECSP993264 A EC SP993264A EC SP993264 A ECSP993264 A EC SP993264A EC SP993264 A ECSP993264 A EC SP993264A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- aryl
- group
- cycloalkyl
- optionally substituted
- Prior art date
Links
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 title 2
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 150000001336 alkenes Chemical class 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 208000034158 bleeding Diseases 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 150000002429 hydrazines Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Hidrazina derivados de la fórmula (I), donde W representa O, S, CO, NR , (CR R ) m, o CR ; X representa CO, NR , (CH2 ) n, CR Centro de Derechos Humanos o ; Y representa CO, NR , (CH2) p, o Centro de Derechos Humanos ; Z representa CO, CS, SO2, o CH2, m significa 0 o 1 , N y p individualmente cada stand de 0, 1, o 2; R representa alquilo inferior, inferior alkenyl, la disminución de los cicloalquilos, la disminución de los cicloalquilos inferior-alquilo, aril o aril-alquilo inferior; R representa alquilo inferior, alkenyl más bajos, menor cicloalquilos, la disminución de los cicloalquilos-alquilo inferior o un grupo de la fórmula V-aril, V-heterocyclyl o - (CH2) q-CH = CR R ; R , R , R , R y R representan cada uno independientemente de hidrógeno, opcionalmente sustituido alquilo inferior, inferior alkenyl, cicloalquilos inferior, inferior cicloalquilos inferior-alquilo, aril, aril-alquilo inferior, heterocyclyl o inferior heterocyclyl - alquilo; o R y R , junto con el átomo de carbono al que se adjunta un formulario de 3 - a 8 miembros de anillo, o R y R o R y R , junto con los átomos de nitrógeno a la que se adjunta un formulario de 3 - a 8 miembros de anillo, o R y R junto con el sp átomos de carbono a las que se adjuntan forman un fundido más bajos cycloalkenyl, aril o heteroaryl anillo, o R , ya sea con R o R representan en conjunto más bajos alqueno en el que un grupo CH2 es opcionalmente sustituido por un heteroatom, o bien R o R ya sea con R o R representan en conjunto más bajos alqueno en el que un grupo CH2 es opcionalmente sustituido por un heteroatom, o R y R representan en conjunto más bajos alqueno en el que un grupo CH2 es opcionalmente sustituido por un heteroatom; V representa un espaciador grupo; R y R representan en conjunto más bajos alqueno en el que un grupo CH2 es opcionalmente sustituidopor un heteroatom, y q está para 1 ó 2, con las salvedades que (i) a menos uno de W, X e Y representa uno de los heteroátomos se ha indicado anteriormente para estos sustituyentes o CO, (ii) Z representa el CO o SO2 o cuando CS W representa O; (iii) W, X, Y y Z no son todos de CO y (iv) W, X e Y no son todos NR , NR NR , respectivamente; pharmaceutically aceptable y sus sales inhiben la liberación de factor de necrosis tumoral alfa (TNF-alfa) a partir de células. Se pueden utilizar como medicamentos, especialmente en el tratamiento de la inflamación y enfermedades autoinmunes, osteoartritis, enfermedades respiratorias, tumores, caquexia, las enfermedades cardiovasculares, fiebre, hemorragia y sepsisHydrazine derivatives of formula (I), where W represents O, S, CO, NR, (CR R) m, or CR; X represents CO, NR, (CH2) n, CR Center for Human Rights or; Y represents CO, NR, (CH2) p, or Center for Human Rights; Z represents CO, CS, SO2, or CH2, m means 0 or 1, N and p individually each stand of 0, 1, or 2; R represents lower alkyl, lower alkenyl, the decrease of the cycloalkyl, the decrease of the lower-alkyl, aryl or aryl-lower alkyl cycloalkyl; R represents lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a group of the formula V-aryl, V-heterocyclyl or - (CH2) q-CH = CR R; R, R, R, R and R each independently represent hydrogen, optionally substituted lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl lower-alkyl, aryl, aryl-lower alkyl, heterocyclyl or lower heterocyclyl-alkyl; or R and R, together with the carbon atom to which a 3- to 8-ring member form is attached, or R and R or R and R, together with the nitrogen atoms to which a form of 3 is attached - to 8 ring members, or R and R together with the sp carbon atoms to which they are attached form a molten lower cycloalkenyl, aryl or heteroaryl ring, or R, with either R or R together representing lower alkene wherein a CH2 group is optionally substituted by a heteroatom, or R or R with either R or R together represent lower alkene in which a CH2 group is optionally substituted by a heteroatom, or R and R together represent lower alkene in which a CH2 group is optionally substituted by a heteroatom; V represents a group spacer; R and R together represent lower alkenes in which a CH2 group is optionally substituted by a heteroatom, and q is for 1 or 2, with the caveats that (i) minus one of W, X and Y represents one of the heteroatoms. previously indicated for these substituents or CO, (ii) Z represents CO or SO2 or when CS W represents O; (iii) W, X, Y and Z are not all of CO and (iv) W, X and Y are not all NR, NR NR, respectively; Pharmaceutically acceptable and its salts inhibit the release of tumor necrosis factor alpha (TNF-alpha) from cells. They can be used as medicines, especially in the treatment of inflammation and autoimmune diseases, osteoarthritis, respiratory diseases, tumors, cachexia, cardiovascular diseases, fever, bleeding and sepsis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP993264 ECSP993264A (en) | 1999-12-10 | 1999-12-10 | DERIVATIVES OF CYCLIC HYDRAZINE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP993264 ECSP993264A (en) | 1999-12-10 | 1999-12-10 | DERIVATIVES OF CYCLIC HYDRAZINE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP993264A true ECSP993264A (en) | 2000-08-18 |
Family
ID=42044253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP993264 ECSP993264A (en) | 1999-12-10 | 1999-12-10 | DERIVATIVES OF CYCLIC HYDRAZINE |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP993264A (en) |
-
1999
- 1999-12-10 EC ECSP993264 patent/ECSP993264A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122199T1 (en) | METHODS FOR MOBILIZATION OF PROGNETER / STEM CELL CELLS | |
| ES2166270B1 (en) | DERIVATIVES OF 8-PHENYL-6,9-DIHIDRO- (1,2,4,) TRIAZOLO (3,4-I) PURIN-5-ONA. | |
| DK419086D0 (en) | Heterocyclic Substituted Indoles, Intermediates, Manufacturing Procedures and Drugs | |
| AR068538A1 (en) | 5-MEMBER HETEROCICLIC COMPOUND WITH SUPPRESSING ACTIVITY OF THE ACID SECRETION | |
| PE20020056A1 (en) | PHENYL AMIDES PARA-ARIL OR HETEROARIL SUBSTITUTED AS GLUCOKINASE ACTIVATORS | |
| RU94031155A (en) | Amidine derivatives, method for their production, their using as inhibitors of no-syntase, pharmaceutical composition, method of treatment | |
| AR030279A1 (en) | DERIVATIVES OF PHENYLAMIDE FOR-AMINO SUBSTITUTED ACTIVATOR OF GLUCOQUINASE, A PROCEDURE FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF MEDICINES. | |
| AR070266A1 (en) | DERIVATIVES OF N- (2-AMINO-PHENYL) -AMIDA, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER. | |
| DK0799833T3 (en) | Erythromycin derivatives, processes for their preparation and their use as drugs | |
| AR048820A1 (en) | TIADIAZOLIDINONES AS INHIBITORS OF THE GLUCOGENO SINTASA QUINASA-3 (GSK-3) | |
| GT200000002A (en) | UREAS DIFENILICIAS X - CARBOXYARIL REPLACED AS RAF KINASE INHIBITORS. | |
| SE7601370L (en) | WAY TO PRODUCE NEW THERAPEUTIC ASSOCIATIONS | |
| ES2044874T3 (en) | DERIVATIVES OF MALONIC ACID AND METHODS FOR ITS SYNTHESIS. | |
| AR065131A1 (en) | TRICYCLES DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| EA201170546A1 (en) | NEW HETEROCYCLIC NITROGEN-CONTAINING COMPOUNDS, THEIR OBTAINING AND THEIR APPLICATION AS ANTIBACTERIAL MEDICINES | |
| AR126912A1 (en) | 6-AMINOPYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR MEDICAL USE | |
| PE20070715A1 (en) | DERIVATIVES OF PIRAZINE | |
| NI201000134A (en) | NEW DIHYDROINDOLONE DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| ES2081747B1 (en) | AMIDES DERIVED FROM TIENOPIRROLES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINES. | |
| ES8104990A1 (en) | A PROCEDURE FOR PREPARING N-ACILIC DERIVATIVES OF HETERO CYCLIC AMINIC COMPOUNDS. | |
| EA200200232A1 (en) | INTERLEUKIN-5 INHIBITIVE DERIVATIVES 6-AZAURACIL | |
| ES396212A1 (en) | N-(1-bicyclic aryl-propyl-2)-n'-bicyclic aryl-piperazines | |
| ECSP993264A (en) | DERIVATIVES OF CYCLIC HYDRAZINE | |
| AR053340A1 (en) | DERIVATIVES OF TRIFLUORMETILBENZAMIDA AND ITS THERAPEUTIC USES | |
| DK74988A (en) | PREPARED UNTIL Peptide DERIVATIVES, WHICH HAVE A POLYCYCLIC NITROGEN CONTAINING STRUCTURE, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL AGENTS CONTAINING THEM |